ALG-055009, Publications Co-Administration of Thyroid Hormone Receptor-beta Agonist ALG-055009 and Incretin Receptor Agonists Leads to Synergistic Weight Loss and Modulation of Molecular Pathways Underlying Adipocyte Dysfunction in Diet-Induced Obese Mice
Pevifoscorvir-sodium, Publications Capsid Assembly Modulator ALG-001075 Prevents CCCDNA Formation and HBV DNA Integration in Vitro
Preclinical, Publications ALG-098340, an Investigational, Potent, Pan-Coronavirus 3CLPRO Inhibitor for Pandemic Preparedness
Preclinical, Publications Preclinical Characterization of ALG-093940, a Potent and Orally Bioavailable Small Molecule PD-1/PD-L1 Inhibitor Targeting PD-L1 Dimerization, Internalization and Degradation
Preclinical, Publications Preclinical Characterization of ALG-094295, a Highly Potent and Orally Bioavailable Small Molecule PD-1/PD-L1 Inhibitor Targeting Dimerization, Internalization and Degradation of PD-L1
ALG-097558, Publications Pharmacokinetics of ALG-097558, a Pan-Coronavirus 3CL-Pro Inhibitor, in Renal and Hepatic Impairment
Pevifoscorvir-sodium, Publications High Viral Suppression in Chronic HBV Infection Subjects with Pevifoscorvir Sodium Monotherapy
Pevifoscorvir-sodium, Publications ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial
ALG-055009, Publications Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists